Aurobindo Pharma is developing a range of products including 14 biosimilars as it looks to expand its product portfolio in the US and EU markets. The firm is developing eight inhalers and six nasal sprays, out of which two products have already been filed. Besides developing a range of biosimilar products for US and EU markets, the company is focusing on five products.
Currently, five products are under development, out of which the first two products would be filed towards the end of this year or early next year. Those products would be filed for Europe, which has a fixed timeline of 210 days for approval.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
